| Year |
Citation |
Score |
| 2008 |
Ahn EY, Yan M, Malakhova OA, Lo MC, Boyapati A, Ommen HB, Hines R, Hokland P, Zhang DE. Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis. Proceedings of the National Academy of Sciences of the United States of America. 105: 17103-8. PMID 18952841 DOI: 10.1073/pnas.0802696105 |
0.357 |
|
| 2003 |
Boyapati A, Wilson M, Yu J, Rundell K. SV40 17KT antigen complements dnaj mutations in large T antigen to restore transformation of primary human fibroblasts. Virology. 315: 148-58. PMID 14592767 DOI: 10.1016/S0042-6822(03)00524-5 |
0.429 |
|
| 2002 |
Yu J, Boyapati A, Rundell K. Critical role for SV40 small-t antigen in human cell transformation. Virology. 290: 192-8. PMID 11883184 DOI: 10.1006/Viro.2001.1204 |
0.43 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2007 |
Boyapati A, Yan M, Peterson LF, Biggs JR, Le Beau MM, Zhang DE. A leukemia fusion protein attenuates the spindle checkpoint and promotes aneuploidy. Blood. 109: 3963-71. PMID 17197431 DOI: 10.1182/blood-2006-09-045583 |
0.289 |
|
| 2004 |
Yan M, Burel SA, Peterson LF, Kanbe E, Iwasaki H, Boyapati A, Hines R, Akashi K, Zhang DE. Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development. Proceedings of the National Academy of Sciences of the United States of America. 101: 17186-91. PMID 15569932 DOI: 10.1073/pnas.0406702101 |
0.285 |
|
| 2006 |
Yan M, Kanbe E, Peterson LF, Boyapati A, Miao Y, Wang Y, Chen IM, Chen Z, Rowley JD, Willman CL, Zhang DE. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nature Medicine. 12: 945-9. PMID 16892037 DOI: 10.1038/nm1443 |
0.263 |
|
| 2007 |
Peterson LF, Boyapati A, Ahn EY, Biggs JR, Okumura AJ, Lo MC, Yan M, Zhang DE. Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts. Blood. 110: 799-805. PMID 17412887 DOI: 10.1182/blood-2006-11-019265 |
0.225 |
|
| 2018 |
Gabay C, Msihid J, Zilberstein M, Paccard C, Lin Y, Graham NMH, Boyapati A. Identification of sarilumab pharmacodynamic and predictive markers in patients with inadequate response to TNF inhibition: a biomarker substudy of the phase 3 TARGET study. Rmd Open. 4: e000607. PMID 29556418 DOI: 10.1136/rmdopen-2017-000607 |
0.194 |
|
| 2022 |
Lin N, Damask A, Boyapati A, Hamilton JD, Hamon S, Ternes N, Nivens MC, Penn J, Lopez A, Reid JG, Overton J, Shuldiner AR, Abecasis G, Baras A, Paulding C. UGT1A1 genetic variants are associated with increases in bilirubin levels in rheumatoid arthritis patients treated with sarilumab. The Pharmacogenomics Journal. PMID 35149777 DOI: 10.1038/s41397-022-00269-5 |
0.191 |
|
| 2016 |
Boyapati A, Msihid J, Fiore S, van Adelsberg J, Graham NM, Hamilton JD. Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY. Arthritis Research & Therapy. 18: 225. PMID 27716324 DOI: 10.1186/s13075-016-1132-9 |
0.19 |
|
| 2020 |
Boyapati A, Schwartzman S, Msihid J, Choy E, Genovese MC, Burmester GR, Lam G, Kimura T, Sadeh J, Weinreich DM, Yancopoulos GD, Graham NMH. High Serum Interleukin-6 is Associated With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab from Adalimumab or Methotrexate in a Post Hoc Analysis. Arthritis & Rheumatology (Hoboken, N.J.). PMID 32343882 DOI: 10.1002/art.41299 |
0.18 |
|
| 2007 |
Hines R, Boyapati A, Zhang DE. Cell type dependent regulation of multidrug resistance-1 gene expression by AML1-ETO. Blood Cells, Molecules & Diseases. 39: 297-306. PMID 17590361 DOI: 10.1016/j.bcmd.2007.05.005 |
0.176 |
|
| 2010 |
Lu Z, Cox-Hipkin MA, Windsor WT, Boyapati A. 3-phosphoinositide-dependent protein kinase-1 regulates proliferation and survival of cancer cells with an activated mitogen-activated protein kinase pathway. Molecular Cancer Research : McR. 8: 421-32. PMID 20197379 DOI: 10.1158/1541-7786.MCR-09-0179 |
0.154 |
|
| 2011 |
Ahn EY, DeKelver RC, Lo MC, Nguyen TA, Matsuura S, Boyapati A, Pandit S, Fu XD, Zhang DE. SON controls cell-cycle progression by coordinated regulation of RNA splicing. Molecular Cell. 42: 185-98. PMID 21504830 DOI: 10.1016/j.molcel.2011.03.014 |
0.152 |
|
| 2023 |
Limnander A, Kaur N, Asrat S, Tasker C, Boyapati A, Ben LH, Janczy J, Pedraza P, Abreu P, Chen WC, Godin S, Daniel BJ, Chin H, DeVeaux M, Rodriguez Lorenc K, et al. A therapeutic strategy to target distinct sources of IgE and durably reverse allergy. Science Translational Medicine. 15: eadf9561. PMID 38091405 DOI: 10.1126/scitranslmed.adf9561 |
0.147 |
|
| 2020 |
Strand V, Boklage SH, Kimura T, Joly F, Boyapati A, Msihid J. High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab. Arthritis Research & Therapy. 22: 250. PMID 33081825 DOI: 10.1186/s13075-020-02344-3 |
0.135 |
|
| 2008 |
Okumura AJ, Peterson LF, Okumura F, Boyapati A, Zhang DE. t(8;21)(q22;q22) Fusion proteins preferentially bind to duplicated AML1/RUNX1 DNA-binding sequences to differentially regulate gene expression. Blood. 112: 1392-401. PMID 18511808 DOI: 10.1182/blood-2007-11-124735 |
0.134 |
|
| 2004 |
Boyapati A, Kanbe E, Zhang DE. p53 alterations in myeloid leukemia. Acta Haematologica. 111: 100-6. PMID 14646348 DOI: 10.1159/000074489 |
0.13 |
|
| 2005 |
Peterson LF, Boyapati A, Ranganathan V, Iwama A, Tenen DG, Tsai S, Zhang DE. The hematopoietic transcription factor AML1 (RUNX1) is negatively regulated by the cell cycle protein cyclin D3. Molecular and Cellular Biology. 25: 10205-19. PMID 16287839 DOI: 10.1128/MCB.25.23.10205-10219.2005 |
0.123 |
|
| 2020 |
Gabay C, Burmester GR, Strand V, Msihid J, Zilberstein M, Kimura T, van Hoogstraten H, Boklage SH, Sadeh J, Graham NMH, Boyapati A. Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes. Arthritis Research & Therapy. 22: 70. PMID 32264972 DOI: 10.1186/s13075-020-02163-6 |
0.12 |
|
| 2020 |
Paccaly AJ, Kovalenko P, Parrino J, Boyapati A, Xu C, van Hoogstraten H, Ishii T, Davis JD, DiCioccio AT. Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single-Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate. Journal of Clinical Pharmacology. PMID 32726514 DOI: 10.1002/jcph.1703 |
0.101 |
|
| 2022 |
Devalaraja-Narashimha K, Ehmann PJ, Huang C, Ruan Q, Wipperman MF, Kaplan T, Liu C, Afolayan S, Glass D, Mellis S, Yancopoulos GD, Hamilton JD, MacDonnell S, Hamon SC, Boyapati A, et al. Association of complement pathways with COVID-19 severity and outcomes. Microbes and Infection. 105081. PMID 36494054 DOI: 10.1016/j.micinf.2022.105081 |
0.093 |
|
| 2020 |
Kovalenko P, Paccaly A, Boyapati A, Xu C, St John G, Nivens MC, Davis JD, Rippley R, DiCioccio AT. Population Pharmacodynamic Model of Neutrophil Margination and Tolerance to Describe Effect of Sarilumab on Absolute Neutrophil Count in Patients with Rheumatoid Arthritis. Cpt: Pharmacometrics & Systems Pharmacology. PMID 32453485 DOI: 10.1002/psp4.12534 |
0.092 |
|
| 2021 |
McAleavy M, Zhang Q, Ehmann PJ, Xu J, Wipperman MF, Ajithdoss D, Pan L, Wakai M, Simonson R, Gadi A, Oyejide A, Hamon SC, Boyapati A, Morton LG, Shavlakadze T, et al. The Activin/FLRG pathway associates with poor COVID-19 outcomes in hospitalized patients. Molecular and Cellular Biology. MCB0046721. PMID 34723652 DOI: 10.1128/MCB.00467-21 |
0.088 |
|
| 2011 |
Boyapati A, Ren B, Zhang DE. SERPINB13 is a novel RUNX1 target gene. Biochemical and Biophysical Research Communications. 411: 115-20. PMID 21723253 DOI: 10.1016/J.Bbrc.2011.06.107 |
0.074 |
|
| 2021 |
Boyapati A, Wipperman MF, Ehmann PJ, Hamon S, Lederer DJ, Waldron A, Flanagan JJ, Karayusuf E, Bhore R, Nivens MC, Hamilton JD, Sumner G, Sivapalasingam S. Baseline SARS-CoV-2 Viral Load is Associated With COVID-19 Disease Severity and Clinical Outcomes: Post-Hoc Analyses of a Phase 2/3 Trial. The Journal of Infectious Diseases. PMID 34496013 DOI: 10.1093/infdis/jiab445 |
0.063 |
|
| 2023 |
Di Rocco M, Forleo-Neto E, Pignolo RJ, Keen R, Orcel P, Funck-Brentano T, Roux C, Kolta S, Madeo A, Bubbear JS, Tabarkiewicz J, Szczepanek M, Bachiller-Corral J, Cheung AM, Dahir KM, ... ... Boyapati A, et al. Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial. Nature Medicine. PMID 37770652 DOI: 10.1038/s41591-023-02561-8 |
0.055 |
|
| 2022 |
Sivapalasingam S, Lederer DJ, Bhore R, Hajizadeh N, Criner G, Hosain R, Mahmood A, Giannelou A, Somersan-Karakaya S, O'Brien MP, Boyapati A, Parrino J, Musser BJ, Labriola-Tompkins E, Ramesh D, et al. Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19: A Randomized Clinical Trial. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 35219277 DOI: 10.1093/cid/ciac153 |
0.022 |
|
| Hide low-probability matches. |